Literature DB >> 31069454

Call to arms: need for radiobiology in molecular radionuclide therapy.

Samantha Y A Terry1, Julie Nonnekens2,3, An Aerts4, Sarah Baatout4, Marion de Jong2, Bart Cornelissen5, Jean-Pierre Pouget6,7,8,9.   

Abstract

Mesh：

Year:  2019        PMID： 31069454     DOI： 10.1007/s00259-019-04334-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  9 in total

1.  Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial.

Authors:  Michela Del Prete; François-Alexandre Buteau; Frédéric Arsenault; Nassim Saighi; Louis-Olivier Bouchard; Alexis Beaulieu; Jean-Mathieu Beauregard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-11-30       Impact factor: 9.236

Review 2.  Radiation-induced bystander signalling in cancer therapy.

Authors:  Kevin M Prise; Joe M O'Sullivan
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

3.  Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Authors:  Jonathan Strosberg; Ghassan El-Haddad; Edward Wolin; Andrew Hendifar; James Yao; Beth Chasen; Erik Mittra; Pamela L Kunz; Matthew H Kulke; Heather Jacene; David Bushnell; Thomas M O'Dorisio; Richard P Baum; Harshad R Kulkarni; Martyn Caplin; Rachida Lebtahi; Timothy Hobday; Ebrahim Delpassand; Eric Van Cutsem; Al Benson; Rajaventhan Srirajaskanthan; Marianne Pavel; Jaime Mora; Jordan Berlin; Enrique Grande; Nicholas Reed; Ettore Seregni; Kjell Öberg; Maribel Lopera Sierra; Paola Santoro; Thomas Thevenet; Jack L Erion; Philippe Ruszniewski; Dik Kwekkeboom; Eric Krenning
Journal:  N Engl J Med       Date:  2017-01-12       Impact factor: 91.245

4.  Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors.

Authors:  Lisa Bodei; Mark Kidd; Giovanni Paganelli; Chiara M Grana; Ignat Drozdov; Marta Cremonesi; Christopher Lepensky; Dik J Kwekkeboom; Richard P Baum; Eric P Krenning; Irvin M Modlin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-02       Impact factor: 9.236

5.  Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission.

Authors:  René H Verheijen; Leon F Massuger; Benedict B Benigno; Agamemnon A Epenetos; Alberto Lopes; John T Soper; Janica Markowska; Rostislav Vyzula; Tom Jobling; Gordon Stamp; Gregory Spiegel; Dennis Thurston; Theo Falke; Joanna Lambert; Michael V Seiden
Journal:  J Clin Oncol       Date:  2006-02-01       Impact factor: 44.544

6.  Alpha emitter radium-223 and survival in metastatic prostate cancer.

Authors:  C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

Review 7.  Introduction to radiobiology of targeted radionuclide therapy.

Authors:  Jean-Pierre Pouget; Catherine Lozza; Emmanuel Deshayes; Vincent Boudousq; Isabelle Navarro-Teulon
Journal:  Front Med (Lausanne)       Date:  2015-03-17

8.  Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force.

Authors:  Caroline Stokke; Pablo Minguez Gabiña; Pavel Solný; Francesco Cicone; Mattias Sandström; Katarina Sjögreen Gleisner; Carlo Chiesa; Emiliano Spezi; Maria Paphiti; Mark Konijnenberg; Matt Aldridge; Jill Tipping; Michael Wissmeyer; Boudewijn Brans; Klaus Bacher; Carsten Kobe; Glenn Flux
Journal:  EJNMMI Phys       Date:  2017-11-21

9.  Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib.

Authors:  Julie Nonnekens; Melissa van Kranenburg; Cecile E M T Beerens; Mustafa Suker; Michael Doukas; Casper H J van Eijck; Marion de Jong; Dik C van Gent
Journal:  Theranostics       Date:  2016-07-18       Impact factor: 11.556
  9 in total
  5 in total

1.  Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response.

Authors:  Danny Feijtel; Gabriela N Doeswijk; Nicole S Verkaik; Joost C Haeck; Daniela Chicco; Carmelina Angotti; Mark W Konijnenberg; Marion de Jong; Julie Nonnekens
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

2.  Rhenium Perrhenate (188ReO4) Induced Apoptosis and Reduced Cancerous Phenotype in Liver Cancer Cells.

Authors:  Samieh Asadian; Abbas Piryaei; Nematollah Gheibi; Bagher Aziz Kalantari; Mohamad Reza Davarpanah; Mehdi Azad; Valentina Kapustina; Mehdi Alikhani; Sahar Moghbeli Nejad; Hani Keshavarz Alikhani; Morteza Mohamadi; Anastasia Shpichka; Peter Timashev; Moustapha Hassan; Massoud Vosough
Journal:  Cells       Date:  2022-01-17       Impact factor: 6.600

3.  Combination Strategies to Improve Targeted Radionuclide Therapy.

Authors:  Tiffany G Chan; Edward O'Neill; Christine Habjan; Bart Cornelissen
Journal:  J Nucl Med       Date:  2020-10-09       Impact factor: 10.057

4.  EANM position paper on the role of radiobiology in nuclear medicine.

Authors:  An Aerts; Uta Eberlein; Sören Holm; Roland Hustinx; Mark Konijnenberg; Lidia Strigari; Fijs W B van Leeuwen; Gerhard Glatting; Michael Lassmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-29       Impact factor: 9.236

5.  Imaging DNA Damage Repair In Vivo After 177Lu-DOTATATE Therapy.

Authors:  Edward O'Neill; Veerle Kersemans; P Danny Allen; Samantha Y A Terry; Julia Baguña Torres; Michael Mosley; Sean Smart; Boon Quan Lee; Nadia Falzone; Katherine A Vallis; Mark W Konijnenberg; Marion de Jong; Julie Nonnekens; Bart Cornelissen
Journal:  J Nucl Med       Date:  2019-11-22       Impact factor: 11.082
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.